Argenx secures $1.5 billion in liquid assets to develop its strategic vision

Argenx is a biotechnological company that develops antibody-based drugs. The company is planning to become a global immunology company in 2021, and its liquid assets have reached $1.5 billion in 2019. The main goal of the large company’s portfolio...

Argenx secures $1.5 billion in liquid assets to develop its strategic vision
Argenx is a biotechnological company that develops antibody-based drugs. The company is planning to become a global immunology company in 2021, and its liquid assets have reached $1.5 billion in 2019. The main goal of the large company’s portfolio is to realize its "Argenx 2021" integrated business vision. Argenx creates medicines to treat diseases with unmet medical needs.